Luciferase News and Research

RSS

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Researchers evaluated the use of receptor decoys for SARS-CoV-2 based on soluble forms of ACE2 for immunological prophylaxis and management of COVID-19 through the use of AAV vectors.

16 Jan 2023

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

Researchers discovered that the spike protein of SARS-CoV-2 is susceptible to cleavage at the disulfide bonds, and the vulnerability to reductive cleavage varies across variants, with the Omicron variant family being highly susceptible to reduction.

10 Jan 2023

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

In a recent study posted to the bioRxiv* preprint server, researchers at Emory University used severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Washington (WA.1) and Omicron (BA.1) strains to test for mutations that could result in resistance to the antiviral drug nirmatrelvir.

8 Jan 2023

What is the role of SARS-CoV-2 non-structural protein 2 in repressing host antiviral immunity?

Researchers uncovered a novel mechanism that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and other coronaviruses (CoVs) use to exploit host antiviral immune system to facilitate their replication.

5 Jan 2023

Study shows angiotensin-converting enzyme 2 decoy protein as a promising anti-SARS-CoV-2 agent

Researchers presented a microbody recombinant decoy protein with high affinity to angiotensin-converting enzyme 2 (ACE2) as an option for coronavirus disease 2019 (COVID-19) treatment.

5 Jan 2023

What is the global state of SARS-CoV-2 seroprevalence in children?

Researchers conducted a systematic review to assess global pediatric SARS-CoV-2 seroprevalence.

3 Jan 2023

Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs

Researchers measured the antibodies against SARS-CoV-2 from nasal fluid, saliva, and plasma to compare the antibody levels between blood and mucosal fluids.

14 Dec 2022

What is the association between farnesoid X receptor inhibition and protection against COVID-19?

Researchers assessed the association between farnesoid X receptor (FXR) inhibition and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.

9 Dec 2022

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

Isolated monoclonal antibodies neutralize SARS-CoV-2 Delta and Omicron variants.

28 Nov 2022

SARS-CoV-2 ‘Deltacron’ variant exhibits immune-escape properties similar to Omicron BA.1

The SARS-CoV-2 Deltacron does not exhibit higher transmissibility or immune evasion than the Omicron BA.1 variant.

16 Nov 2022

Structure-directed mutagenesis produces thermostable SARS-CoV-2 spike protein trimers with potential vaccine booster applications

Researchers investigated the change in the stability, antigenicity, and protein expression of the SARS-CoV-2 spike protein trimer using structure-directed mutagenesis to alter a cavity in the core of the spike protein.

14 Nov 2022

Environmental toxicants contribute to obesity and metabolic disease

In a recent study published in the Current Opinion in Pharmacology journal, researchers assessed the impact of environmental toxicants and brown adipose tissue (BAT) on obesity and metabolic disorders.

4 Nov 2022

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

A new study evaluated the neutralizing antibody titers against the SARS-CoV-2 Omicron variant and its sub-lineages after two and three doses of the Novavax protein nanoparticle vaccine NVX-CoV2373.

31 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

Luciferase News and Research

Researchers report that vectored expression of a high-affinity ACE2 microbody protein establishes a high degree of protection from SARS-CoV-2

Spike protein mutations in Omicron subvariants increase their susceptibility to reductive cleavage of disulfide bonds

New research on nirmatrelvir resistance in SARS-CoV-2 using powerful replicon cell culture systems

What is the role of SARS-CoV-2 non-structural protein 2 in repressing host antiviral immunity?

Study shows angiotensin-converting enzyme 2 decoy protein as a promising anti-SARS-CoV-2 agent

What is the global state of SARS-CoV-2 seroprevalence in children?

Study indicates need for developing mucosal vaccines to induce potent immune responses at sites where SARS-CoV-2 infection occurs

What is the association between farnesoid X receptor inhibition and protection against COVID-19?

Isolated monoclonal antibodies targeting SARS-CoV-2 S1/S2 cleavage effective against Delta and Omicron

SARS-CoV-2 ‘Deltacron’ variant exhibits immune-escape properties similar to Omicron BA.1

Structure-directed mutagenesis produces thermostable SARS-CoV-2 spike protein trimers with potential vaccine booster applications

Environmental toxicants contribute to obesity and metabolic disease

New research suggests booster dose of Novavax NVX-CoV2373 vaccine is effective against SARS-CoV-2 Omicron subvariants

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

Study reveals conserved and divergent host responses to infections with SARS-CoV-2 variants of concern

DNA damage in older age increases expression of ACE2 and SARS-CoV-2 infection risk

New antiviral mechanism of action for an FDA-approved thiopurine known as 6-thioguanine

The potential of nanobody engineering in the development of SARS-CoV-2 antivirals and diagnostic tools

Self-replicating intradermal RNA vaccine against SARS-CoV-2

New study provides comparison of replicating and non-replicating vaccines against SARS-CoV-2

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News